irinotecan has been researched along with Kahler Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebara, K; Ichimura, E; Miyakawa, Y; Miyazaki, O; Morino, T; Nagai, D; Nakajima, N; Okamoto, K; Onda, T; Sekine, K | 1 |
| Ding, J; Iida, S; Inagaki, A; Inagaki, H; Ishida, T; Ito, A; Kayukawa, S; Komatsu, H; Kusumoto, S; Mori, F; Nakagawa, C; Oguri, T; Ri, M; Sanda, T; Suzuki, A; Ueda, R; Yano, H | 1 |
| Anderson, KC; Burger, R; Catley, L; Chauhan, D; Denis, L; Hideshima, T; Munshi, NC; Podar, K; Richardson, P; Shringarpure, R; Son, MT; Tai, YT; Tassone, P | 1 |
3 other study(ies) available for irinotecan and Kahler Disease
| Article | Year |
|---|---|
Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Micelles; Multiple Myeloma; Prodrugs; Xenograft Model Antitumor Assays | 2014 |
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Male; Mice; Mice, SCID; Multiple Myeloma; Topoisomerase I Inhibitors; Transfection; Xenograft Model Antitumor Assays | 2008 |
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Camptothecin; Cell Communication; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Activation; fas Receptor; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lymphoma; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stromal Cells; Up-Regulation | 2004 |